Clinical trials
Multiple myeloma clinical trials
A cancer of plasma cells in the bone marrow that affects the blood and bones. We’re tracking 540 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05546723RecruitingPhase 1
Study drug for multiple myeloma after several prior treatments
This Phase 1 trial tests LMY-920 in people with multiple myeloma that has returned or stopped responding after multiple standard therapies. It’s meant to see if the treatment can work and to better understand its safety and side effects in this situation.
Cleveland, OhioAges 18 years+ - NCT07689058RecruitingPhase 2
CAR-T therapy for relapsed or refractory multiple myeloma
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
Rawalpindi, Punjab ProvinceAges 18 years+ - NCT06659276Recruiting
Comparing two imaging methods for multiple myeloma
This trial compares two whole-body imaging scans (full-body MRI using DWI and a PET/CT scan) to see which does a better job detecting and staging active multiple myeloma. If you have been newly diagnosed or are being evaluated for suspected symptomatic myeloma, joining could help doctors learn which test is best for planning your care.
BolognaAges 18 years+ - NCT07674498Recruiting
Immune health in older adults with advanced myeloma
This trial studies the immune system of adults 65 and older with multiple myeloma that has come back or not responded to treatment. It looks at how their immune fitness may affect their ability to receive newer therapies like CAR-T cells or bispecific antibodies.
Anderlecht, Brussels CapitalAges 65 years+ - NCT07657312RecruitingPhase 2
Infliximab to prevent side effects during myeloma treatment
This trial tests if infliximab, a drug that calms the immune system, can prevent cytokine release syndrome (a serious side effect) when patients receive teclistamab or talquetamab for multiple myeloma that has returned or not responded to treatment.
Columbus, OhioAges 18 years+ - NCT07652281RecruitingPhase 1
Study of SHR-5421 for multiple myeloma
This trial tests a new drug, SHR-5421, for people with multiple myeloma that has come back or stopped responding to treatment. It aims to see if the drug is safe and how well it works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07652138RecruitingPhase 1
RN1201 injection for newly diagnosed multiple myeloma
This trial tests a new drug called RN1201 as a first-line treatment for multiple myeloma, a blood cancer. The study aims to see if it is safe and effective for patients who have never been treated for this condition before.
Suzhou, JiangsuAges 18–70 - NCT07637578RecruitingPhase 2
Elranatamab infusions for relapsed or refractory myeloma
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
Denver, ColoradoAges 18 years+ - NCT06245629Recruiting
Comparing two drug combos for relapsed multiple myeloma
This trial looks at two different drug combinations given before a second stem cell transplant for multiple myeloma that has come back after first treatment. It aims to see if adding two extra drugs (bortezomib and bendamustine) to the standard drug (melphalan) works better than using the standard drug alone.
UppsalaAges 18 years+ - NCT07589634RecruitingPhase 2
Tocilizumab to prevent side effects from ramantamig in multiple myeloma
This study tests whether a drug called tocilizumab can prevent serious side effects (cytokine release syndrome) when combined with a new cancer drug called ramantamig. You'll be eligible if you have multiple myeloma that has come back or stopped responding to prior treatments.
Goodyear, ArizonaAges 18 years+ - NCT06700395RecruitingPhase 1
Study of TQB2029 for multiple myeloma patients
This trial tests a new injectable drug, TQB2029, for people with multiple myeloma. It aims to see if the drug is safe and effective, and may be an option if you have measurable disease and are in relatively good health.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07585760RecruitingPhase 2
Two-drug treatment for newly diagnosed myeloma with kidney problems
This trial tests a combination of two drugs, CM336 and isatuximab, for people newly diagnosed with multiple myeloma who also have kidney problems caused by the disease. The goal is to see if this combination can help control the myeloma while also improving kidney function.
TianjinAges 18–80 - NCT07581704RecruitingPhase 1
Sirolimus plus immunotherapy for relapsed multiple myeloma
This study tests whether a drug called sirolimus, given before certain immunotherapy treatments (teclistamab or talquetamab), helps these treatments work better against multiple myeloma. These immunotherapies teach your immune cells to attack myeloma cells.
Iowa City, IowaAges 18 years+ - NCT05053607Recruiting
Text and Fitbit monitoring during isatuximab treatment
This trial follows people with multiple myeloma who are getting isatuximab through a vein (IV). It tests how well real-world health tracking (text/app messages and Fitbit data) works during treatment, and whether it can help care teams understand your experience.
Houston, TexasAges 18 years+ - NCT06083207RecruitingPhase 1/Phase 2
IBI3003 for multiple myeloma that has returned or not responded
This trial tests an investigational drug called IBI3003 in people with multiple myeloma that has come back or hasn't responded to previous treatments. The goal is to see if it is safe and effective.
Wollongong, New South WalesAges 18 years+ - NCT07564219Recruiting
Beta-Hydroxybutyrate to Boost CAR-T Cell Therapy in Multiple Myeloma
This trial tests whether a natural metabolite called beta-hydroxybutyrate can strengthen CAR-T cell therapy (a type of cancer-fighting cell treatment) in multiple myeloma patients. The goal is to help your immune cells work better against your cancer.
Hamburg, Free and Hanseatic City of HamburgAges 18 years+ - NCT06209606RecruitingEarly Phase 1
Blood test study for multiple myeloma progression
This study is testing whether a blood test that measures a protein called BCMA can help doctors know if your multiple myeloma is getting worse. You may be able to join if your myeloma has come back or not responded to at least two prior treatments, and you have not taken the drug Ruxolitinib before.
West Hollywood, CaliforniaAges 18 years+ - NCT06561854RecruitingPhase 3
Comparing multiple myeloma treatment with and without dexamethasone
This trial tests whether adding dexamethasone to an antibody-based combination therapy works better for multiple myeloma that has come back after previous treatments. If you have had 1 to 3 prior therapies and are eligible for one of two standard drug regimens, this study may help find the best approach for you.
ParisAges 18 years+ - NCT07555938RecruitingPhase 3
New drug combination for previously treated multiple myeloma
This trial tests whether a new drug called cevostamab, combined with two existing myeloma drugs (pomalidomide and dexamethasone), works better than standard treatment for people whose myeloma has returned or stopped responding to prior therapy. You would receive this combination to see if it helps control your disease.
Duarte, CaliforniaAges 18 years+ - NCT07547007Recruiting
Exercise Program to Improve Life Quality After Myeloma Treatment
This study tests whether a 6-month personalized exercise program—done partly at home and partly at a center—can improve quality of life for patients with multiple myeloma (a blood cancer) who are receiving ongoing chemotherapy or targeted drugs. The program is tailored to your abilities and fits into your regular hospital visits.
AnnecyAges 61 years+ - NCT07529782RecruitingPhase 1
Safety and Efficacy of HDP-101 in Relapsed or Refractory Multiple Myeloma
This trial tests a new drug called HDP-101 in patients with multiple myeloma that has come back or stopped responding to previous treatments. The study aims to find the safest and most effective dose and to see if this drug can help control the cancer.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT07518186RecruitingPhase 3
Comparing Two New Myeloma Treatments: JNJ-79635322 vs Teclistamab
This study compares two new antibody-based drugs (JNJ-79635322 and teclistamab) to see which works better for multiple myeloma that has come back or stopped responding to prior treatment. Both drugs are designed to help your immune system fight myeloma cells.
Birmingham, AlabamaAges 18 years+ - NCT07497165Recruiting
Epunamin plus DECP for returning or resistant multiple myeloma
This trial tests a combination of the study drug Epunamin with four chemotherapy drugs (dexamethasone, cisplatin, etoposide, and cyclophosphamide) for people whose multiple myeloma has come back or stopped responding to earlier treatments.
Taiyuan, ShanxiAges 18–75 - NCT07490613RecruitingPhase 1
Study of SHR-3836 for people with multiple myeloma
This trial tests a new drug called SHR-3836 for patients with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if the drug is safe and how it works against the cancer.
Suzhou, JiangsuAges 18 years+
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple myeloma?
- Yes. Clin2 currently lists 540 recruiting multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.